Core Insights - Biotalys is undergoing a strategic refocus to concentrate resources on its highest-priority programs and streamline operations [1][2] - The company aims to reduce total cash burn by €20 million until the end of 2028 compared to its current operating structure [2] - The focus will be on advancing its lead biofungicide assets, particularly EVOCA NG and BioFun-6, while maintaining partnerships for other programs [3] Organizational Changes - Biotalys plans to right-size its organizational structure and suspend early-stage activities to lower operating expenses [2] - The workforce will be reduced by 30 employees to align with the new strategy [4] - The company confirms its cash runway extends into May 2026 and is exploring financing options to support its refocused portfolio [4][9] Product Development - EVOCA NG is expected to be Biotalys' first commercial biofungicide, with a planned launch in the USA in 2029 and in Europe in 2030, targeting a market worth over USD 1.1 billion [5] - The U.S. EPA has approved the first-generation version of EVOCA, facilitating a shorter regulatory review process for EVOCA NG [6] Company Background - Biotalys is an AgTech company focused on developing protein-based biocontrol solutions for sustainable crop protection [7] - The company was founded in 2013 as a spin-off from the VIB and is based in Ghent, Belgium [7] - Biotalys employs an average of 59 employees as of 2025 [11]

Core Viewpoint - Biotalys has entered a strategic partnership with 21st.BIO to enhance the production of its protein-based biocontrol solutions, aiming for commercially competitive costs and efficient large-scale manufacturing [1][2][3]. Group 1: Partnership Details - The collaboration will utilize 21st.BIO's advanced precision fermentation platform, which has been refined over four decades and is proven in commercial use [2]. - This partnership is expected to strengthen Biotalys' AGROBODY platform and support the development of its product portfolio, including the upcoming commercial product EVOCA™ NG [3][4]. Group 2: Product Development and Market Strategy - EVOCA NG is designed to control fungal diseases such as Botrytis and powdery mildew, targeting a combined market of approximately USD 1.2 billion in the U.S., Europe, and Brazil [7]. - Biotalys anticipates a shorter regulatory review process for EVOCA NG due to its similarity to the previously approved EVOCA product [8]. Group 3: Financial and Funding Plans - Biotalys confirms its cash runway extends into May 2026 and is considering additional financing options, including equity from institutional investors, to support the commercialization of EVOCA NG and further development of its AGROBODY biocontrols [5][6].

Core Viewpoint - Biotalys has received regulatory approval from the U.S. EPA for its first protein-based biofungicide, EVOCA, marking a significant milestone in agricultural technology [1][5]. Group 1: Product Overview - EVOCA is a precision biocontrol solution targeting fungal pathogens such as botrytis and powdery mildew in high-value fruits and vegetables, while minimizing risks to beneficial organisms and the environment [2]. - The product is designed to provide a novel solution that combines the efficacy of traditional chemistries with the environmental benefits of biological solutions [5][11]. - EVOCA has demonstrated strong performance in trials across various regions, climates, and crops, making it a versatile option for growers [10]. Group 2: Regulatory Progress - With EPA approval, Biotalys can now proceed with state registrations in California and Florida, critical regions for fruit and vegetable production in the U.S. [3][9]. - The company is also advancing the regulatory submission for EVOCA NG, a next-generation product expected to have a shorter review process due to its similar active ingredient and improved formulation [4]. Group 3: Market Potential - Biotalys anticipates that EVOCA NG will be registered in the U.S. by 2028-29 and in the EU and Brazil by 2029-30, with a combined market potential of approximately USD 1.2 billion [4]. - The approval of EVOCA and the upcoming registration of EVOCA NG highlight the potential of Biotalys' technology to shape the future of agriculture [5]. Group 4: Safety and Compliance - The EPA has exempted EVOCA's active ingredient residues on treated crops from tolerance requirements, indicating a strong safety profile for the product [6]. - EVOCA has received a FRAC code, recognizing its unique mode of action and contributing to its credibility in the market [7]. Group 5: Company Background - Biotalys is an AgTech company focused on developing precision biocontrol solutions based on proteins, aiming to address key crop pests and diseases throughout the agricultural value chain [11]. - Founded in 2013 as a spin-off from the VIB, Biotalys is based in Ghent, Belgium, and is listed on Euronext Brussels [11].